|
Emmanuelle Marie Charpentier, born in 1968 in Juvisy-sur-Orge in France, is a French researcher in Microbiology, Genetics and Biochemistry. == Biography == Emmanuelle Charpentier began studying Biochemistry, Microbiology and Genetics at the Pierre and Marie Curie University (UPMC) in Paris. In 1995, she took a doctorate on research conducted at the Pasteur Institute. After her dissertation defense, she was active at several universities and hospitals in the United States. Some of those were Rockefeller University, New York University Langone Medical Center, (Skirball Institute of Biomolecular Medicine ) (all in New York) and St. Jude Children’s Research Hospital in Memphis. After five years, she returned to Europe, first to Vienna and thereafter to Umeå University in Sweden where she holds a position as research leader at The Laboratory for Molecular Infection Medicine Sweden (MIMS) and is also a visiting professor at (Umeå Centre for Microbial Research (UCMR) ). She is Private Docent in Microbiology (2006, University of Vienna) and Docent in Medical Microbiology (2013, Umeå University).〔http://www.mpg.de/9343740/infektionsbiologie-charpentier〕 In 2013, she was appointed Professor at Helmholtz Centre for Infection Research in Braunschweig and an Alexander von Humboldt Professorship at Hannover Medical School (MHH) in Hannover, Germany. In 2015, Charpentier accepted the offer from the German Max Planck Society to become scientific member and director of the new Max Planck Institute of Infection Biology in Berlin. Charpentier will maintain her position as visiting professor at Umeå University, where a new donation from the Kempe Foundations and the Knut and Alice Wallenberg Foundation gives her the opportunity to offer more young researchers positions within research groups at |MIMS. Charpentier is best known for her role in deciphering the molecular mechanisms of the bacterial CRISPR-Cas9 immune system and repurposing it into a tool for genome editing. In collaboration with Jennifer Doudna's laboratory, Charpentier's laboratory showed that Cas9 could be used to make cuts in any DNA sequence desired.〔(【引用サイトリンク】CRISPR Therapeutics, About us )〕 The method they developed involved the combination of Cas9 with easily created synthetic "guide RNA" molecules. Researchers worldwide have employed this method to efficiently edit the DNA sequences of plants, animals, and laboratory cell lines. Charpentier has been awarded several international prizes, awards and acknowledgements, a few of which are the Breakthrough Prize in Life Sciences and the Gruber Foundation International Prize in Genetics. Also, in spring 2015, Time Magazine appointed Charpentier one of the 100 most influential people in the world (together with Jennifer Doudna). 抄文引用元・出典: フリー百科事典『 ウィキペディア（Wikipedia）』 ■ウィキペディアで「Emmanuelle Charpentier」の詳細全文を読む スポンサード リンク
|